Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MenPenta
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MenPenta is an investigational pentavalent meningococcal vaccine (MenABCWY) developed by Sanofi for active immunization against invasive disease caused by *Neisseria meningitidis* serogroups A, B, C, W, and Y. It combines components targeting MenACWY (similar to MenQuadfi or Nimenrix) and MenB (similar to Bexsero), aiming for a fully liquid format with broader strain coverage and improved safety profile through non-lipidated fHbp. The vaccine is being evaluated in pediatric populations, including infants (~2 months), toddlers (12-15 months), and children (2-9 years), to simplify immunization schedules compared to separate MenACWY and MenB vaccines.[2][6][9][11]
- Other names
- MenABCYW vaccineSanofi Pentavalent Meningococcal VaccinemRNA-1405mRNA1405mRNA 1405
02
Targets
Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)
Beyond the preview
Go deeper on MenPenta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MenPenta.